CSF3R and chronic myelogenous leukemia, BCR-ABL1 positive: Nevertheless, whether JAK2 or SRC inhibitors are of benefit to patients with CSF3R mutations remains to be investigated, since the majority of studies conducted regarding CSF3R are related to CML.